Cathy Watkins

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

C. Lance Cowey, Chirag Amin, Raj S. Pruthi et al. · Journal of Clinical Oncology · 2010 · 197 citations · Full text

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)

M. Fukuoka, Yi‐Cheng Wu, S. Thongprasert et al. · Journal of Clinical Oncology · 2009 · 119 citations

Versus Carboplatin/paclitaxel, Progression-free Survival, Pathology +18

Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy

Raj S. Pruthi, J. Eric Derksen, Dominic T. Moore et al. · Clinical Cancer Research · 2006 · 97 citations

Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC)

Jared Gollob, T. Richmond, Jennifer Jones et al. · Journal of Clinical Oncology · 2006 · 38 citations

Immunology, Sorafenib 400, Pharmacotherapy +17

A phase II trial of lapatinib in hormone refractory prostate cancer

Young E. Whang, Cassandra N. Moore, Andrew J. Armstrong et al. · Journal of Clinical Oncology · 2008 · 14 citations

Tyrosine Kinase Inhibitor, Urology, Phase Ii Trial +12